Enovis (NYSE:ENOV) Sets New 12-Month Low – Time to Sell?

Shares of Enovis Corporation (NYSE:ENOV) hit a new 52-week low on Friday . The stock traded as low as $20.55 and last traded at $21.2060, with a volume of 1502415 shares trading hands. The stock had previously closed at $21.97.

Analyst Upgrades and Downgrades

Several research analysts recently weighed in on the stock. Zacks Research downgraded shares of Enovis from a “strong-buy” rating to a “hold” rating in a research note on Monday, June 1st. BTIG Research reissued a “buy” rating and issued a $39.00 target price on shares of Enovis in a research note on Friday, May 22nd. Wells Fargo & Company cut their target price on shares of Enovis from $42.00 to $40.00 and set an “overweight” rating for the company in a research note on Friday, May 8th. Needham & Company LLC boosted their target price on shares of Enovis from $49.00 to $52.00 and gave the company a “buy” rating in a research note on Thursday, February 26th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Enovis in a research note on Friday, April 10th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Enovis has a consensus rating of “Moderate Buy” and an average target price of $44.50.

Enovis Stock Performance

The stock’s 50 day moving average price is $24.07 and its 200 day moving average price is $24.63. The company has a current ratio of 2.04, a quick ratio of 1.05 and a debt-to-equity ratio of 0.87. The company has a market cap of $1.22 billion, a price-to-earnings ratio of -1.07 and a beta of 1.38.

Enovis (NYSE:ENOV) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.89 EPS for the quarter, beating analysts’ consensus estimates of $0.82 by $0.07. Enovis had a negative net margin of 49.92% and a positive return on equity of 10.32%. The company had revenue of $589.15 million during the quarter, compared to the consensus estimate of $572.02 million. During the same quarter in the prior year, the company posted $0.81 EPS. The company’s quarterly revenue was up 5.4% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. On average, analysts expect that Enovis Corporation will post 3.65 EPS for the current fiscal year.

Institutional Trading of Enovis

A number of institutional investors have recently modified their holdings of ENOV. AQR Capital Management LLC grew its holdings in shares of Enovis by 12.5% during the 1st quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock worth $2,363,000 after purchasing an additional 7,072 shares during the period. Goldman Sachs Group Inc. grew its holdings in shares of Enovis by 37.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after purchasing an additional 73,116 shares during the period. Empowered Funds LLC grew its holdings in shares of Enovis by 13.0% during the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after purchasing an additional 749 shares during the period. EverSource Wealth Advisors LLC grew its holdings in shares of Enovis by 125.4% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after purchasing an additional 707 shares during the period. Finally, Amundi grew its holdings in shares of Enovis by 24,405.0% during the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock worth $328,000 after purchasing an additional 9,762 shares during the period. Hedge funds and other institutional investors own 98.45% of the company’s stock.

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.